Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Shouyao Holdings (beijing) Co. Ltd

Clinical trials sponsored by Shouyao Holdings (beijing) Co. Ltd, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug SY-9453 targets Hard-to-Treat cancers in early trial Results expected Feb 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 1

Targeted pill shows promise for Hard-to-Treat lung cancer subtype

Disease control Ongoing

This phase 3 trial tests an experimental drug called SY-5007 in people with advanced non-small cell lung cancer that has a specific genetic change (RET fusion). The drug is a daily pill designed to block the cancer-driving RET protein. The study aims to see how well the drug shri…

Phase 3 • Sponsor: Shouyao Holdings (Beijing) Co. LTD • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC